{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:11:32Z","timestamp":1791144692086,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1124\/jpet.103.062984","type":"journal-article","created":{"date-parts":[[2004,3,26]],"date-time":"2004-03-26T18:07:46Z","timestamp":1080324466000},"page":"79-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Primaquine-Induced Hemolytic Anemia: Susceptibility of Normal versus Glutathione-Depleted Rat Erythrocytes to 5-Hydroxyprimaquine"],"prefix":"10.1016","volume":"309","author":[{"given":"Zachary S.","family":"Bowman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"John E.","family":"Oatis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Jollow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.103.062984_bib1","doi-asserted-by":"crossref","unstructured":"Agarwal S, Gupta UR, Gupta RC, Anand N, and Agarwal SS (1988) Susceptibility of glucose-6-phosphate dehydrogenase deficient red cells to primaquine enantiomers and two putative metabolites. I. Effect on reduced glutathione, methemoglobin content and release of hemoglobin. Biochem Pharmacol 37: 4605-4609.","DOI":"10.1016\/0006-2952(88)90327-9"},{"key":"10.1124\/jpet.103.062984_bib2","doi-asserted-by":"crossref","unstructured":"Allahyari R, Strother A, Fraser IM, and Verbiscar AJ (1984) Synthesis of certain hydroxy analogues of the antimalarial drug primaquine and their in vitro methemoglobin-producing and glutathione-depleting activity in human erythrocytes. J Med Chem 27: 407-410.","DOI":"10.1021\/jm00369a031"},{"key":"10.1124\/jpet.103.062984_bib3","doi-asserted-by":"crossref","unstructured":"Baird JK, McCormick GJ, and Canfield CJ (1986) Effects of nine synthetic putative metabolites of primaquine on activity of the hexose monophosphate shunt in intact human red blood cells in vitro. Biochem Pharmacol 35: 1099-1106.","DOI":"10.1016\/0006-2952(86)90145-0"},{"key":"10.1124\/jpet.103.062984_bib4","doi-asserted-by":"crossref","unstructured":"Bolchoz LJ, Budinsky RA, McMillan DC, and Jollow DJ (2001) Primaquine-induced hemolytic anemia: formation and hemotoxicity of the arylhydroxylamine metabolite 6-methoxy-8-hydroxylaminoquinoline. J Pharmacol Exp Ther 297: 509-515.","DOI":"10.1016\/S0022-3565(24)29564-1"},{"key":"10.1124\/jpet.103.062984_bib5","doi-asserted-by":"crossref","unstructured":"Bolchoz LJ, Morrow JD, McMillan DC, and Jollow DJ (2002) Primaquine-induced hemolytic anemia: effect of 6-methoxy-8-hydroxylaminoquinoline on rat erythrocyte sulfhydryl status, membrane lipids, cytoskeletal proteins and morphology. J Pharmacol Exp Ther 303: 1121-1129.","DOI":"10.1124\/jpet.102.041459"},{"key":"10.1124\/jpet.103.062984_bib6","unstructured":"Degowin RL, Eppes RB, Powell RD, and Carson PE (1966) The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphatedehydrogenase deficiency. Bull World Health Organ 35: 165-179."},{"key":"10.1124\/jpet.103.062984_bib7","unstructured":"Dern RJ, Beutler E, and Alving AS (1955) The hemolytic effect of primaquine. V. Primaquine sensitivity as a manifestation of a multiple drug sensitivity. J Lab Clin Med 45: 30-39."},{"key":"10.1124\/jpet.103.062984_bib8","doi-asserted-by":"crossref","unstructured":"Elderfield RC, Mertel HE, Mitch RT, Wempen IM, and Werble E (1955) Synthesis of primaquine and certain of its analogs. J Am Chem Soc 77: 4816-4819.","DOI":"10.1021\/ja01623a038"},{"key":"10.1124\/jpet.103.062984_bib9","doi-asserted-by":"crossref","unstructured":"Evelyn KA and Malloy HT (1938) Microdetermination of oxyhemoglobin, methemoglobin and sulfhemoglobin in a single sample of blood. J Biol Chem 126: 655-662.","DOI":"10.1016\/S0021-9258(18)73873-8"},{"key":"10.1124\/jpet.103.062984_bib10","doi-asserted-by":"crossref","unstructured":"Fletcher KA, Barton PF, and Kelly JA (1988) Studies on the mechanisms of oxidation in the erythrocyte by metabolites of primaquine. Biochem Pharmacol 37: 2683-2690.","DOI":"10.1016\/0006-2952(88)90263-8"},{"key":"10.1124\/jpet.103.062984_bib11","doi-asserted-by":"crossref","unstructured":"Gaetani GF, Mareni C, Salvidio E, Galiano S, Meloni T, and Arese P (1979) Favism: erythrocyte metabolism during haemolysis and reticulocytosis. Br J Haematol 43: 39-48.","DOI":"10.1111\/j.1365-2141.1979.tb03717.x"},{"key":"10.1124\/jpet.103.062984_bib12","doi-asserted-by":"crossref","unstructured":"Grossman SJ, Simson J, and Jollow DJ (1992) Dapsone-induced hemolytic anemia: effect of N-hydroxy dapsone on the sulfhydryl status and membrane proteins of rat erythrocytes. Toxicol Appl Pharmacol 117: 208-217.","DOI":"10.1016\/0041-008X(92)90239-O"},{"key":"10.1124\/jpet.103.062984_bib13","doi-asserted-by":"crossref","unstructured":"Harrison J Jr and Jollow DJ (1987) Contribution of aniline metabolites to anilineinduced methemoglobinemia. Mol Pharmacol 32: 423-431.","DOI":"10.1016\/S0026-895X(25)13019-8"},{"key":"10.1124\/jpet.103.062984_bib14","doi-asserted-by":"crossref","unstructured":"Kain KC and Keystone JS (1998) Malaria in travelers. Epidemiology, disease and prevention. Infect Dis Clin North Am 12: 267-284.","DOI":"10.1016\/S0891-5520(05)70005-2"},{"key":"10.1124\/jpet.103.062984_bib15","doi-asserted-by":"crossref","unstructured":"Link CM, Theoharides AD, Anders JC, Chung H, and Canfield CJ (1985) Structureactivity relationships of putative primaquine metabolites causing methemoglobin formation in canine hemolysates. Toxicol Appl Pharmacol 81: 192-202.","DOI":"10.1016\/0041-008X(85)90155-3"},{"key":"10.1124\/jpet.103.062984_bib16","doi-asserted-by":"crossref","unstructured":"McMillan DC, Bolchoz LJ, and Jollow DJ (2001) Favism: effect of divicine on rat erythrocyte sulfhydryl status, hexose monophosphate shunt activity, morphology and membrane skeletal proteins. Toxicol Sci 62: 353-359.","DOI":"10.1093\/toxsci\/62.2.353"},{"key":"10.1124\/jpet.103.062984_bib17","doi-asserted-by":"crossref","unstructured":"Shanks GD, Kain KC, and Keystone JS (2001) Malaria chemoprophylaxis in the age of drug resistance. II. Drugs that may be available in the future. Clin Infect Dis 33: 381-385.","DOI":"10.1086\/321866"},{"key":"10.1124\/jpet.103.062984_bib18","unstructured":"Tracy JW and Webster LT (2001) Drugs used in the chemotherapy of protozoal infections: Malaria, in Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics (Hardman JG and Limbird LE eds) pp 1069-1095, McGraw-Hill Companies, New York."},{"key":"10.1124\/jpet.103.062984_bib19","doi-asserted-by":"crossref","unstructured":"Vasquez-Vivar J and Augusto O (1990) ESR detection of free radical intermediates during autoxidation of 5-hydroxyprimaquine. Free Rad Res Commun 9: 383-389.","DOI":"10.3109\/10715769009145698"},{"key":"10.1124\/jpet.103.062984_bib20","doi-asserted-by":"crossref","unstructured":"Vasquez-Vivar J and Augusto O (1992) Hydroxylated metabolites of the antimalarial drug primaquine. Oxidation and redox cycling. J Biol Chem 267: 6848-6854.","DOI":"10.1016\/S0021-9258(19)50504-X"},{"key":"10.1124\/jpet.103.062984_bib21","doi-asserted-by":"crossref","unstructured":"Vasquez-Vivar J and Augusto O (1994) Oxidative activity of primaquine metabolites on rat erythrocytes in vitro and in vivo. Biochem Pharmacol 47: 309-316.","DOI":"10.1016\/0006-2952(94)90022-1"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524312522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524312522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.103.062984","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:49:18Z","timestamp":1739998158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524312522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S0022356524312522"],"URL":"https:\/\/doi.org\/10.1124\/jpet.103.062984","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primaquine-Induced Hemolytic Anemia: Susceptibility of Normal versus Glutathione-Depleted Rat Erythrocytes to 5-Hydroxyprimaquine","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.103.062984","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2004 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}